Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 3;27(6):109896.
doi: 10.1016/j.isci.2024.109896. eCollection 2024 Jun 21.

The public-private research ecosystem in the genome editing era

Rami M Major  1 , Arlene M Davis  2 , Gail E Henderson  2 , Greg Inamine  3 , John M Conley  3
Affiliations

The public-private research ecosystem in the genome editing era

Rami M Major et al. iScience. .

Abstract

Biomedical research in the US has long been conducted in a public-private (PP) "ecosystem." Today, especially with gene therapies and genome editing-based medicine, publicly funded researchers frequently hand off their research to the private sector for clinical development, often to small, venture capital-funded startups in which they have a financial interest. This trend raises ethical questions about conflicts of interest, effectiveness of regulatory oversight, and justice in therapy access, that we are addressing in a multi-year, multidisciplinary study of the evolving governance of genome editing. This paper draws on interviews with scientists working across the PP divide and their private sector business and financial partners. We find little concern about potential ethical dilemmas, with two exceptions expressed by public sector scientists: concerns about inequitable access to treatments due to disparities in wealth, ethnicity, and health insurance benefits; and about whether their private collaborators' profit motive may affect their research objectives.

Keywords: Ethical issues in genetics; Medical ethics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

None
Graphical abstract
See this image and copyright information in PMC

References

    1. Bodenheimer T. Uneasy Alliance — Clinical Investigators and the Pharmaceutical Industry. N. Engl. J. Med. 2000;342:1539–1544. doi: 10.1056/nejm200005183422024. - DOI - PubMed
    1. Shuchman M. Commercializing Clinical Trials — Risks and Benefits of the CRO Boom. N. Engl. J. Med. 2007;357:1365–1368. doi: 10.1056/NEJMp078176. - DOI - PubMed
    1. Tierney W.M., Meslin E.M., Kroenke K. Industry Support of Medical Research: Important Opportunity or Treacherous Pitfall? J. Gen. Intern. Med. 2016;31:228–233. doi: 10.1007/s11606-015-3495-z. - DOI - PMC - PubMed
    1. Walker R.L. In: Encyclopeida of Philosophy. 2 ed. Borchert D., editor. Macmillan Reference; 2006. Bioethics.
    1. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research . US Department of Health and Human Services. 1979. The Belmont report: Ethical principles and guidelines for the protection of human subjects of research. - PubMed

LinkOut - more resources